# A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma

> **NCT01989325** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Advanced Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib, proteasome inhibitor; intravenous
- **DRUG:** Filanesib, KSP(Eg5) inhibitor; intravenous
- **DRUG:** Dexamethasone, steroid; oral or intravenous
- **DRUG:** Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous

## Key facts

- **NCT ID:** NCT01989325
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-02
- **Final completion:** 2016-05
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01989325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01989325, "A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01989325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*